Please wait a minute...
浙江大学学报(医学版)  2014, Vol. 43 Issue (6): 683-687    DOI: 10.3785/j.issn.1008-292.2014.11.008
专题报道     
肿瘤根治术后行肝动脉化疗栓塞术联合药物化疗的原发性肝癌患者远期生存分析
邱广平,刘杰,范华
宁波市第二医院介入科, 浙江 宁波 315010
Longterm survival analysis of primary hepatocarcinoma patients received transcatheter arterial chemoembolization plus chemotherapy after radical resection
QIU Guang-ping, LIU Jie, FAN Hua
Department of Interventional Treatment, Ningbo No.2 Hospital, Ningbo 315010, China
全文: PDF(580 KB)  
摘要: 

目的:分析原发性肝癌(HCC)患者根治切除术后联合应用肝动脉化疗栓塞术(TACE)和药物化疗的生存情况。 方法:选取在宁波市第二医院随访5年以上的HCC术后患者143例,按术后治疗方法不同分为介入组(术后予以TACE)、化疗组(术后予以FOLPOX4化疗方案)及综合组(术后予以TACE+FOLPOX4化疗方案)。采用多因素Cox回归模型分析HCC患者术后预后的影响因素(包括性别、年龄、肝炎病史、肿瘤直径、术后肝功能、术后甲胎蛋白水平、术后Karnofsky performance status评分及术后治疗方案),并绘制各组生存曲线,计算1、2、3年累积生存率,采用Kaplan-Meier方法进行比较。 结果:术后甲胎蛋白水平与患者生存时间呈负相关,为独立危险因素,回归系数为0.01,相对危险度为1.00;术后进一步治疗能提高HCC术后患者的生存时间,为保护因素,其中采取综合方案的回归系数为-2.37,相对危险度为0.07,影响生存时间的权重比高于另外两组,而介入组的权重比高于化疗组。术后1、2、3年累计生存率综合组分别为78.35%、69.16%、24.43%,介入组分别为76.87%、62.48%、24.72%,化疗组分别为62.23%、43.22%、19.54%。 结论:术后甲胎蛋白水平与HCC患者术后生存质量存在负相关,术后甲胎蛋白水平监测可为手术效果及预后判断提供参考。TACE运用于HCC术后能有效降低患者病死率,联合药物化疗能有效延长HCC患者术后生存时间。

关键词 肝细胞/外科学肝肿瘤/外科学肝肿瘤/病理学肝动脉化学栓塞治疗性手术后期间回归分析甲胎蛋白存活率    
Abstract

Objective: To evaluate the survival of hepatocellular carcinoma (HCC) patients received prophylactic use of transcatheter arterial chemoembolization (TACE) after radical resection. Methods: One hundred and forty-three cases of HCC from Ningbo No.2 Hospital were divided into intervention prevention group, chemotherapy prevention group and comprehensive prevention group according to different methods of HCC prevention. All patients were followed-up for more than 5 years after TACE, chemotherapy(FOLPOX4) or TACE+ FOLPOX4. Cox regression model of multiple factors analysis was used for analyzing impact factors on HCC prognosis. Survival rate was compared with Kaplan-meier method. Results: Alpha-fetoprotein (AFP) was negatively correlated with the survival time of patients, as an independent risk factor with the regression coefficient of 0.01 and the relative risk of 1.00. Prevention of postoperative increased survival time of patients with HCC, which was a protective factor. The regression coefficient for comprehensive prevention was -2.37 and the relative risk was 0.07, the weight of comprehensive prevention on lifetime was higher than that of other two prevention methods, followed by TACE prevention group. One-year, 2-year, 3-year cumulative survival rates in comprehensive prevention group were 78.35%, 69.16%, 24.43%, that in TACE prevention group were 76.87%, 62.48%, 24.72%, and that in chemotherapy prevention group were 62.23%, 43.22%, 19.54%, respectively. Conclusion: AFP was negative correlation with the survival time of postoperative HCC patients, monitored which of postoperative HCC patients can provide a reference for effect and prognosis of surgery. Application of TACE in HCC patients with postoperative effective in reducing mortality, which prolong the survival time of HCC patients might be extended further by combined chemotherapy based on its own advantages and disadvantages.

Key wordsCarcinoma    hepatocellular/surgery    Liver neoplasms/suegery    Liver neoplasms/pathology    Hepatic artery    Chemoembolization    therapeutic    Postoperative period    Regression analysis    Alpha-fetoproteins    Survival rate
收稿日期: 2014-05-19     
Corresponding author: QIU Guang-ping, E-mail: qiuguangping_reho@163.com   
作者简介: 邱广平(1972-),男,学士,副主任医师,主要从事介入放射学研究; E-mail: qiuguangping_reho@163.com
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
邱广平

引用本文:

邱广平,等. 肿瘤根治术后行肝动脉化疗栓塞术联合药物化疗的原发性肝癌患者远期生存分析[J]. 浙江大学学报(医学版), 2014, 43(6): 683-687.
QIU Guangping,et al. Longterm survival analysis of primary hepatocarcinoma patients received transcatheter arterial chemoembolization plus chemotherapy after radical resection. Journal of ZheJiang University(Medical Science), 2014, 43(6): 683-687.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-292.2014.11.008      或      http://www.zjujournals.com/xueshu/med/CN/Y2014/V43/I6/683

[1] 蔡成,王建平,钟志凤,戴志慧,王庆华,董武真,施红旗,刘庆伟,杜金林. 缺氧诱导因子1α和CD133预测直肠癌患者新辅助放化疗疗效的临床研究[J]. 浙江大学学报(医学版), 2017, 46(1): 36-43.
[2] 陈刚,张鼎,应亚草,王志峰,陶伟,朱皓,张景峰,彭志毅. 国产载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[J]. 浙江大学学报(医学版), 2017, 46(1): 44-51.
[3] 夏光发 等. 新辅助化疗前后激素受体变化的乳腺癌患者辅助内分泌治疗的疗效[J]. 浙江大学学报(医学版), 2016, 45(6): 614-619.
[4] 沈志森 等. RNA干扰沉默DJ-1基因对Hep-2细胞裸鼠移植瘤生长的影响[J]. 浙江大学学报(医学版), 2016, 45(4): 349-355.
[5] 娄鹏荣 等. 靶向RAD18的小干扰RNA对人食管鳞癌ECA-109细胞增殖和化疗敏感性的影响[J]. 浙江大学学报(医学版), 2016, 45(4): 364-370.
[6] 郑江江 等. 肿瘤相关成纤维细胞CD10表达在结直肠腺瘤癌变和复发中的意义[J]. 浙江大学学报(医学版), 2016, 45(4): 335-341.
[7] 何苗 等. 特殊疾病医疗保险对糖尿病患者治疗费用的影响及相关因素分析[J]. 浙江大学学报(医学版), 2016, 45(3): 323-329.
[8] 边薇 等. 临时血液透析对维持性腹膜透析患者生存预后的影响[J]. 浙江大学学报(医学版), 2016, 45(2): 195-200.
[9] 李增山. 胃肠胰神经内分泌肿瘤分类及病理学进展[J]. 浙江大学学报(医学版), 2016, 45(1): 10-23.
[10] 徐芳英 等. 神经内分泌分化在胃腺癌进展及患者预后中的意义[J]. 浙江大学学报(医学版), 2016, 45(1): 24-30.
[11] 刘琴 等. 促泌素蛋白的分布和功能[J]. 浙江大学学报(医学版), 2016, 45(1): 56-60.
[12] 滕晓东 等. 肺神经内分泌肿瘤病理诊断进展[J]. 浙江大学学报(医学版), 2016, 45(1): 36-44.
[13] 王教辰 等. 乳腺黏液癌神经内分泌分化和肾母细胞瘤蛋白1表达特征及其意义[J]. 浙江大学学报(医学版), 2016, 45(1): 45-50.
[14] 来翀 等. 转移性肾细胞癌靶向治疗的分子生物学基础[J]. 浙江大学学报(医学版), 2016, 45(1): 91-97.
[15] 徐力等. SN-38与索拉非尼联合应用体外抗肝癌效果及其机制[J]. 浙江大学学报(医学版), 2015, 44(5): 486-492.